AI-Enabled Discovery
Supporting All Modalities

De Novo Design Excellence:

• • 9.8% hit rate at round 1 zero-shot prediction demonstrate reliable platform performance
• • 35% hit rate at round 2 iteration project achieving effective reinforcement learning performance
• • 50% overall success rate in de novo design over novel targets without structure information

Affinity Maturation Leadership:

• • Industry-leading 85.7% success rate across 42 projects at round 1 zero-shot prediction
• • 21.5% hit rate at round 1 zero-shot prediction substantially reduce the number wet lab test
• • Strong round 2 iteration performance with 43.8% hit rate
• • Achieves affinity improvements from dozens to thousands fold increase
• • Delivers potencies reaching picomolar levels

Computational Efficiency:

The SentinusAI® platform achieves these superior results while reducing computational costs by 10,000x compared to traditional 3D-based modeling approaches, making protein design accessible and economically viable for a broader range of applications and without dependence on 3D structure resolution.

Competitive Landscape Analysis:

Recent market entrants have struggled to achieve comparable performance metrics. While some competitors report qualitative improvements like being "actively refining" or achieving "single-digit nanomolar" results, Ainnocence's platform delivers quantifiable, reproducible success rates since 2021 that translate directly to commercial viability.